» Articles » PMID: 36497192

Wnt Signaling in the Development of Bone Metastasis

Overview
Journal Cells
Publisher MDPI
Date 2022 Dec 11
PMID 36497192
Authors
Affiliations
Soon will be listed here.
Abstract

Wnt signaling occurs through evolutionarily conserved pathways that affect cellular proliferation and fate decisions during development and tissue maintenance. Alterations in these highly regulated pathways, however, play pivotal roles in various malignancies, promoting cancer initiation, growth and metastasis and the development of drug resistance. The ability of cancer cells to metastasize is the primary cause of cancer mortality. Bone is one of the most frequent sites of metastases that generally arise from breast, prostate, lung, melanoma or kidney cancer. Upon their arrival to the bone, cancer cells can enter a long-term dormancy period, from which they can be reactivated, but can rarely be cured. The activation of Wnt signaling during the bone metastasis process was found to enhance proliferation, induce the epithelial-to-mesenchymal transition, promote the modulation of the extracellular matrix, enhance angiogenesis and immune tolerance and metastasize and thrive in the bone. Due to the complexity of Wnt pathways and of the landscape of this mineralized tissue, Wnt function during metastatic progression within bone is not yet fully understood. Therefore, we believe that a better understanding of these pathways and their roles in the development of bone metastasis could improve our understanding of the disease and may constitute fertile ground for potential therapeutics.

Citing Articles

Molecular mechanism of bone metastasis in breast cancer.

Sui L, Wang J, Jiang W, Song X, Ye L Front Oncol. 2024; 14:1401113.

PMID: 39605887 PMC: 11599183. DOI: 10.3389/fonc.2024.1401113.


Apoptotic signaling pathways in bone metastatic lung cancer: a comprehensive analysis.

Zhang Y, Zheng Y, Zhang J, Xu C, Wu J Discov Oncol. 2024; 15(1):310.

PMID: 39060849 PMC: 11282049. DOI: 10.1007/s12672-024-01151-5.


What enlightenment has the development of lung cancer bone metastasis brought in the last 22 years.

Chen Y, Chen X, He R, Huang Z, Lu H, Huang H World J Clin Oncol. 2024; 15(6):765-782.

PMID: 38946828 PMC: 11212609. DOI: 10.5306/wjco.v15.i6.765.


Crosstalk between Wnt and bone morphogenetic protein signaling during osteogenic differentiation.

Arya P, Saranya I, Selvamurugan N World J Stem Cells. 2024; 16(2):102-113.

PMID: 38455105 PMC: 10915952. DOI: 10.4252/wjsc.v16.i2.102.


Wnt/β-catenin-driven EMT regulation in human cancers.

Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R Cell Mol Life Sci. 2024; 81(1):79.

PMID: 38334836 PMC: 10857981. DOI: 10.1007/s00018-023-05099-7.


References
1.
Sterling J, Edwards J, Martin T, Mundy G . Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone. 2010; 48(1):6-15. DOI: 10.1016/j.bone.2010.07.015. View

2.
Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A . TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res. 2014; 29(8):1886-99. DOI: 10.1002/jbmr.2215. View

3.
Ke H, Richards W, Li X, Ominsky M . Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):747-83. DOI: 10.1210/er.2011-1060. View

4.
Saneyoshi T, Kume S, Amasaki Y, Mikoshiba K . The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature. 2002; 417(6886):295-9. DOI: 10.1038/417295a. View

5.
Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View